Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katerine Van Rietschoten"'
Autor:
Gavin Bennett, Sophie Watcham, Gemma Mudd, Katerine Van Rietschoten, Philip Huxley, Liuhong Chen, Silvia Pavan, Amy E. Caruso Brown, Johanna Lahdenranta, Nicholas Keen
Publikováno v:
Molecular Cancer Therapeutics. 19:1385-1394
The EphA2 receptor is found at high levels in tumors and low levels in normal tissue and high EphA2 expression in biopsies is a predictor of poor outcome in patients. Drug discovery groups have therefore sought to develop EphA2-based therapies using
Autor:
Ann Christin Baranski, Liuhong Chen, Katerine Van Rietschoten, Klaus Kopka, Karin Leotta, Uwe Haberkorn, Daniel Teufel, Gemma Mudd, Edward Walker, Ursula Schierbaum, Silvia Pavan, Gavin Bennett, Matthias Eder, Spencer Campbell, Ulrike Bauder-Wüst, Helen Harrison, Catherine Stace
Publikováno v:
Cancer Research. 79:841-852
Molecular imaging of cancers using probes specific for tumor-associated target proteins offers a powerful solution for providing information regarding selection of targeted therapy, patient stratification, and response to therapy. Here we demonstrate
Autor:
Eric Haines, Katerine Van Rietschoten, Punit Upadhyaya, Marianna Kleyman, Elizabeth Repash, Tom Li Stephen, Jessica Kublin, Johanna Lahdenranta, Sailaja Battula, Rachel Dods, Kristen Hurov, Jun Ma, Nicholas Keen, Rachid Lani, Gemma Mudd, Philip Brandish, Julia Kristensson, Kevin Mcdonnell, Helen Harrison, Liuhong Chen, Fanglei You
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundIn contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, term
Autor:
Peter U. Park, Amy E. Caruso Brown, Gemma Mudd, Helen Harrison, Katerine Van Rietschoten, Michael Rigby, Johanna Lahdenranta, Heather K. Allen, Eric Haines, Gavin Bennett, Philip Jeffrey, Nicholas Keen, Paul Beswick, Liuhong Chen, Sophie Watcham
Publikováno v:
Molecular Cancer Therapeutics. 18:C061-C061
Small molecule toxin conjugates offer a novel approach to tumor antigen specific targeting, allowing reduced systemic exposures and efficient tumor penetration of cytotoxic payloads, compared to large antibody toxin conjugates. BT8009 is a Bicycle To
Autor:
Tjing-Tjing Hu, Catherine Stace, Philippe Barbeaux, Helen Harrison, Gavin Bennett, Tine Van Bergen, Katerine Van Rietschoten, Daniel Teufel, Elke Vermassen, Jean H.M. Feyen, Silvia Pavan, Marc Vanhove, François Le Floch
Publikováno v:
Journal of medicinal chemistry. 61(7)
Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Preclinical evidence implicates the activity of plasma kal
Autor:
Sophie Watcham, Gavin Bennett, Katerine Van Rietschoten, Paul Beswick, Liuhong Chen, Gemma Mudd, Phil Jeffrey, Amy E. Caruso Brown, Peter U. Park, Helen Harrison, Michael Rigby, Maria Koehler, Heather K. Allen, Nicholas Keen
Publikováno v:
Cancer Research. 79:4479-4479
We have identified a Nectin-4 targeting peptide for delivery of cytotoxic agents to Nectin-4 expressing tumors. Nectin-4 is a cell adhesion molecule, that is highly expressed in certain tumor types, including bladder, TNBC and NSCLC, but has a restri